Protein Capped Metal Nanoparticles Inhibits Tau Aggregation in Alzheimer’s Disease

The Alzheimer’s disease (AD) therapeutic research is yielding large number of potent molecules. The nanoparticle-based therapeutics against the protein aggregation in AD is also taking a lead especially with amyloid beta as a primary target. In this work, we have screened for first time, the protein capped (PC) metal nanoparticles for their potency in inhibiting Tau aggregation in vitro. We present a novel function of PC-CdS nanoparticles as a potent Tau aggregation inhibitor by fluorescence spectrometry, SDS-PAGE and Electron microscopy. We demonstrate that the biologically synthesized PC-metal nanoparticles, iron oxide and cadmium sulphide do not affect the viability of neuroblastoma cells. Moreover, PC-CdS nanoparticles show dual property of inhibition as well as disaggregation of Tau. Thus, the nanoparticles can take a lead as potent Tau aggregation inhibitors and can be modified for specific drug delivery due to very small size. This current work presents unprecedented strategy to design anti-Tau aggregation drugs, which provides interesting insights to understand the role of biological nanostructures in Alzheimer’s disease.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  2019-05-31

• Fields of study

  Not labeled

• Identifiers
  DOI 10.26434/chemrxiv.8208026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Conformational Dynamics of Intracellular Tau Protein Revealed by CD and SAXS.

  2017cited by this paper
• Global Conformation of Tau Protein Mapped by Raman Spectroscopy.

  2017cited by this paper
• The amyloid hypothesis of Alzheimer's disease at 25 years

  2016cited by this paper
• Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.

  2016cited by this paper
• Tau and neurodegenerative disease: the story so far

  2016cited by this paper
• Adsorption and separation of amyloid beta aggregates using ferromagnetic nanoparticles coated with charged polymer brushes.

  2015cited by this paper
• Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity.

  2015cited by this paper
• High Throughput Screening Method to Explore Protein Interactions with Nanoparticles

  2015cited by this paper
• Tau in physiology and pathology

  2015cited by this paper
• Synthesis, characterization and biocompatibility of cadmium sulfide nanoparticles capped with dextrin for in vivo and in vitro imaging application

  2015cited by this paper
• Nanoparticles in relation to peptide and protein aggregation

  2014cited by this paper
• New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.

  2014cited by this paper
• Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

  2014cited by this paper
• Progress and developments in tau aggregation inhibitors for Alzheimer disease.

  2013cited by this paper
• Potential synergy between tau aggregation inhibitors and tau chaperonemodulators

  2013cited by this paper
• Molecular Pathology of Alzheimer's Disease

  2013cited by this paper
• Multifunctional PEGylated nanoclusters for biomedical applications.

  2013cited by this paper
• Semiconductor quantum dots for bioimaging and biodiagnostic applications.

  2013cited by this paper
• Toxicity of cadmium sulfide (CdS) nanoparticles against Escherichia coli and HeLa cells.

  2013cited by this paper
• Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases.

  2012cited by this paper
• Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy

  2012cited by this paper
• The Effect of Nanoparticles on Amyloid Aggregation Depends on the Protein Stability and Intrinsic Aggregation Rate

  2011cited by this paper
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  2011cited by this paper
• Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation.

  2010cited by this paper
• The molecular pathology of Alzheimer’s disease

  2008cited by this paper
• Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles.

  2008cited by this paper
• Nucleation of protein fibrillation by nanoparticles

  2007cited by this paper
• Protein misfolding, functional amyloid, and human disease.

  2006cited by this paper
• Extracellular biosynthesis of magnetite using fungi.

  2006cited by this paper
• Tau aggregation is driven by a transition from random coil to beta sheet structure.

  2005cited by this paper
• Post-translational modifications of tau protein in Alzheimer’s disease

  2005cited by this paper
• Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro.

  2005cited by this paper
• Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

  2004cited by this paper
• Chemical synthesis of magnetic nanoparticles.

  2003cited by this paper
• BIOSYNTHESIS OF METAL NANOPARTICLES USING FUNGI AND ACTINOMYCETE

  2003cited by this paper
• Enzyme mediated extracellular synthesis of CdS nanoparticles by the fungus, Fusarium oxysporum.

  2002cited by this paper
• BIOREDUCTION OF AUCL4− IONS BY THE FUNGUS, VERTICILLIUM SP. AND SURFACE TRAPPING OF THE GOLD NANOPARTICLES FORMED

  2001cited by this paper
• Drug, Healthcare and Patient Safety Dovepress Safety Aspects and Rational Use of a Naproxen + Esomeprazole Combination in the Treatment of Rheumatoid Disease

  year unknowncited by this paper

• Initiation and modulation of Tau protein phase separation by the drug suramin

  2023cites this paper
• In-silico tuning of the nano-bio interface by molecular dynamics method: Amyloid beta targeting with two-dimensional metal-organic frameworks

  2023cites this paper
• Drug Discovery and Development Targeting Dementia

  2023cites this paper
• Recent advances in nanotechnology for combating Alzheimer's disease

  2023cites this paper
• An optimistic approach to nanotechnology in Alzheimer's disease management: An overview

  2023cites this paper
• Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression

  2023cites this paper
• Rationally designed cyclic peptides and nanomaterials as ‘next-generation’ anti-amyloid therapeutics

  2023cites this paper
• Amyposomes, a nanotechnological chaperone with anti-amyloidogenic activity

  2023cites this paper
• Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer's disease.

  2023cites this paper
• The inhibitory effect of Curcumin-Artemisinin co-amorphous on Tau aggregation and Tau phosphorylation.

  2022cites this paper
• Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis

  2022cites this paper
• Nano-mediated Strategies for Metal Ion–Induced Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases

  2022cites this paper
• Inhibition Of Tau Protein Aggregation By a Chaperone-like β-Boswellic Acid Conjugated To Gold Nanoparticles

  2022cites this paper
• Engineered Nanoparticle-Protein Interactions Influence Protein Structural Integrity and Biological Significance

  2022cites this paper
• Structural characterization and antibacterial activity of silver nanoparticles synthesized using a low-molecular-weight Royal Jelly extract

  2022cites this paper
• Polyethyleneimine stabilized silver nanoparticles as an efficient and selective colorimetric assay for promethazine.

  2022cites this paper
• Comparative study of biogenically synthesized silver and gold nanoparticles of Acacia auriculiformis leaves and their efficacy against Alzheimer's and Parkinson's disease.

  2022cites this paper
• Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease.

  2022cites this paper
• Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy.

  2022cites this paper
• Copper oxide nanoparticles promote amyloid-β-triggered neurotoxicity through formation of oligomeric species as a prelude to Alzheimer's diseases.

  2022cites this paper
• Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders

  2022cites this paper
• The Use of Capping Agents in the Stabilization and Functionalization of Metallic Nanoparticles for Biomedical Applications

  2022cites this paper
• Exosome-based Approaches in the Management of Alzheimer's Disease.

  2022cites this paper
• Investigating neuroprotective roles of Bacopa monnieri extracts: Mechanistic insights and therapeutic implications.

  2022cites this paper
• Nanodelivery of antiretroviral drugs to nervous tissues

  2022cites this paper
• Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease

  2022cites this paper
• Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease

  2021cites this paper
• Effect of Azide Preservative on Thermomechanical Aggregation of Purified Reference Protein Materials.

  2021cites this paper
• Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation

  2021cites this paper
• The application of multifunctional nanomaterials in Alzheimer's disease: A potential theranostics strategy.

  2021cites this paper
• Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

  2021cites this paper
• The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders

  2021cites this paper
• Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

  2021cites this paper
• Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

  2021cites this paper
• Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

  2021cites this paper
• Advances in developing therapeutic strategies for Alzheimer's disease.

  2021cites this paper
• From Small Molecules to Synthesized Polymers: Potential Role in Combating Amyloidogenic Disorders.

  2021cites this paper
• Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends

  2021cites this paper
• New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease

  2021cites this paper
• Amyloid-β-Derived Peptidomimetics Inhibits Tau Aggregation

  2021cites this paper
• Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives

  2021cites this paper
• Acetylcholine esterase inhibitory activity of green synthesized nanosilver by naphthopyrones isolated from marine-derived Aspergillus niger

  2021cites this paper
• Perspective Insights to Bio-Nanomaterials for the Treatment of Neurological Disorders

  2021cites this paper
• Denatured crude protein extracts from the sea anemone Entacmaea quadricolor as capping agents for silver nanoclusters

  2021cites this paper
• Nanotechnology: An Emerging Field in Protein Aggregation and Cancer Therapeutics

  2021cites this paper
• αAu2S nanoparticles: Fungal-mediated synthesis, structural characterization and bioassay

  2021cites this paper
• Photo-Excited Toluidine Blue Disaggregates the Repeat Tau and Modulates End-Binding Protein EB1, Cytoskeletal Structure in Neuronal Cells.

  2020cites this paper
• Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease

  2020cites this paper
• Porphyrin-Armored Gold Nanospheres Modulate the Secondary Structure of α-Synuclein and Arrest Its Fibrillation

  2020cites this paper
• Cobalt-based metal complexes prevent Repeat Tau aggregation and nontoxic to neuronal cells.

  2020cites this paper
• Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer’s Disease

  2020cites this paper
• Phagocytosis of full-length Tau oligomers by Actin-remodeling of activated microglia

  2020cites this paper
• Baicalein Inhibits Heparin-induced Tau Aggregation by Initializing Tau Oligomer Formation 

  2020cites this paper
• Nanotheranostic agents for neurodegenerative diseases.

  2020cites this paper
• Detecting and targeting neurodegenerative disorders using electrospun nanofibrous matrices: current status and applications

  2020cites this paper
• Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

  2020cites this paper
• Heat Stress Modulates the GSK-3β Levels and Tau Phosphorylation

  2020cites this paper
• Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

  2020cites this paper
• Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.

  2020cites this paper
• l-3,4-Dihydroxyphenylalanine templated anisotropic gold nano/micro-roses as potential disrupters/inhibitors of α-crystallin protein and its gleaned model peptide aggregates.

  2020cites this paper
• Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)

  2020cites this paper
• Photodynamic exposure of Rose-Bengal inhibits Tau aggregation and modulates cytoskeletal network in neuronal cells

  2020cites this paper
• Understanding the Structure, Toxicity and Inhibition of IAPP at the Nanoscale

  2020cites this paper
• Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers.

  2019cites this paper
• Nanoneurotoxicity and Potential Nanotheranostics for Alzheimer's Disease.

  2019cites this paper
• Transition metal nickel prevents Tau aggregation in Alzheimer's disease.

  2019cites this paper
• Photoexcited Toluidine Blue Inhibits Tau Aggregation in Alzheimer’s Disease

  2019cites this paper
• Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease.

  2019cites this paper